Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
.
1. Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med. 2020 Dec;383(27):2652–64. DOI: 10.1056/
NEJMra2002697. Available from: https://pubmed.ncbi.nlm.nih.gov/33382932/
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflam-
matory bowel disease in the 21st century: a systematic review of population-based studies. Lancet (London, England). 2017
Dec;390(10114):2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0. Available from: https://www.sciencedirect.com/
science/article/abs/pii/S0140673617324480
3. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gas-
troenterol Hepatol. 2021 Jan;18(1):56–66. DOI: 10.1038/s41575-020-00360-x . Available from: https://pubmed.ncbi.nlm.nih.
gov/33033392/
4. Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn’s disease.
Curr Drug Targets. 2014;15(11):1056–63. DOI:10.2174/1389450115666140908125738. https://www.researchgate.net/publica-
tion/265419102_Catching_the_Therapeutic_Window _of_Opportunity_in_Early_Crohn%27s_Disease
5. D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or con-
ventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial Lancet [Internet] 2008 Feb
6. Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel K V, et al. A biomarker-stratified comparison of top-down versus accele-
rated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label rando-
mised controlled trial. lancet Gastroenterol Hepatol. 2024 May;9(5):415–27. DOI:10.1016/S2468- 1253(24)00034-7. Available
from: https://www.researchgate.net/publication/378428618_A_biomarker- stratified_comparison_of_top-down_versus_acce-
lerated_step- up_treatment_strategies_for_patients_with_newly_diagnosed_Crohn%27s_disease_PROFIL E_a_multicentre_
open-label_randomised_controlled_t
7. Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO Guidelines on Therapeutics in Crohn’s Di-
sease: Medical Treatment. J Crohns Colitis. 2024 Oct;18(10):1531–55. DOI: 10.1093/ecco-jcc/jjae091. Available from: https://
pubmed.ncbi.nlm.nih.gov/38877997/La ética en la investigación médica8. Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F. GETECCU 2020 guidelines for the treat-
ment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol. 2020 Aug;43 Suppl 1:1–57. DOI:
10.1016/j.gastrohep.2020.07.001 . https://pubmed.ncbi.nlm.nih.gov/32807301/
9. Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, et al. The Time Course of Diagnostic Delay in In-
flammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study. J Crohns Colitis. 2017 Aug;11(8):975–80.
DOI: 10.1093/ecco- jcc/jjx041 . Available from: https://pubmed.ncbi.nlm.nih.gov/28333328/
10. Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, et al. Incidence, Clinical Charac-
teristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J Clin Med. 2021
Jun;10(13). doi: 10.3390/jcm10132885. Available from: https://pubmed.ncbi.nlm.nih.gov/34209680/
11. Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An Update on the Selecting The-
rapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD
(IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570–83.
DOI: 10.1053/j.gastro.2020.12.031 . Available from: https://pubmed.ncbi.nlm.nih.gov/33359090/
12. Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bastón I, Ferreiro-Iglesias R, et al. Evaluation of the Risk of Re-
lapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns
Colitis. 2016 Jan;10(1):13–9. DOI: 10.1093/ecco-jcc/jjv158 . Available from: https://pubmed.ncbi.nlm.nih.gov/26351390/
13. Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn’s di-
sease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet (London, England). 2017 Dec;390(10114):2779–89.
DOI: 10.1016/S0140-6736(17)32641-7 . https://pubmed.ncbi.nlm.nih.gov/29096949/
14. + Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis.
lancet Gastroenterol Hepatol. 2021 Jul;6(7):589–95. DOI: 10.1016/S2468-1253(21)00065-0. https://pubmed.ncbi.nlm.nih.
gov/34019798/
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Derechos de autor 2025 Revista Médica-Científica CAMbios HECAM
